Breaking News - Candlesense

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectio...

What risks or uncertainties were highlighted that could influence Innoviva's future performance? Were there any significant one‑time items or non‑recurring expenses that investors should adjust for when evaluating the results? What impact might the reported results have on the stock's short‑term price movement and trading volume?

Symbol: INVA

Earnings

24 days ago

Read more businesswire

Amtech Reports Third Quarter Fiscal 2025 Results

TEMPE, Ariz.--(BUSINESS WIRE)--Amtech Systems, Inc. ("Amtech") (NASDAQ: ASYS), a manufacturer of equipment and consumables for semiconductor fabrication and packaging, today reported results for it...

What risks or uncertainties did management flag that could impact future earnings? How does ASYS's valuation (P/E, EV/EBITDA) compare to peer companies in semiconductor equipment? What are the key market or customer developments influencing the results (e.g., new chiplets, 3‑D packaging demand)?

Symbol: ASYS

Earnings

24 days ago

Read more businesswire

Ark Restaurants Announces Conference Call

NEW YORK--(BUSINESS WIRE)--Ark Restaurants Corp. (NASDAQ:ARKR) will hold a conference call for investors and analysts to discuss financial results for the third quarter ended June 28, 2025 on Tuesd...

How might the disclosed financial results and commentary influence the stock’s momentum and trading volume in the days following the call? Will there be any updates regarding the company's balance sheet strength, such as liquidity or debt refinancing plans? What potential macro‑economic or consumer‑spending trends were highlighted that might impact the restaurant industry outlook?

Symbol: ARKR

Earnings

24 days ago

Read more businesswire

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2...

Are there any new partnership or licensing developments referenced that could influence future growth and stock valuation? What risks remain that could cause another FDA intervention or affect the continuity of product shipments? How might the resumed infusions impact the company’s cash burn and runway given its current balance‑sheet position?

Symbol: SRPT

Earnings

24 days ago

Read more businesswire

Biote Reports Second Quarter 2025 Financial Results

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, toda...

What macro‑economic or industry trends could amplify or mitigate the effects of Biote's restructuring on its financial performance? Are there any changes to Biote's capital allocation strategy, such as R&D spend or capex, that could influence long‑term growth? How might the cultural change initiatives impact employee productivity and operational efficiency moving forward?

Symbol: BTMD

Earnings

24 days ago

Read more businesswire

Bloom Energy Appoints Jim Snabe to Board of Directors

SAN JOSE, Calif.--(BUSINESS WIRE)--Bloom Energy (NYSE: BE), a global leader in power solutions, today announced that technology industry veteran and trusted advisor to businesses and governments, J...

Could Snabe’s network with governments and enterprises open new market opportunities that drive revenue growth? How does this appointment compare to recent board changes at competitors in the renewable energy space? What impact could this have on analyst coverage and forward‑looking earnings estimates?

Symbol: BE

Management

24 days ago

Read more businesswire

Cardlytics Announces Second Quarter 2025 Financial Results

ATLANTA--(BUSINESS WIRE)--Cardlytics, Inc. (NASDAQ: CDLX), a commerce media platform, today announced financial results for the second quarter ended June 30, 2025. "Building on the progress we've m...

What risk factors were disclosed in the earnings release that might affect the company's long‑term growth trajectory? Are there any upcoming catalysts (e.g., product launches, conference presentations) that could impact the stock in the near term? What valuation multiples (e.g., EV/Revenue, P/E) does the market currently price Cardlytics at, and are they justified by the latest results?

Symbol: CDLX

Earnings

24 days ago

Read more businesswire

electroCore Announces Second Quarter 2025 Financial Results

Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024

Are there any risk factors or one‑off items disclosed that could affect future performance? How might the results affect the short‑term technical outlook – potential breakout or pull‑back? What is the company’s revised outlook for the remaining 2025 fiscal year, and does it include any adjustments to pricing or cost structure?

Symbol: ECOR

Earnings

24 days ago

BBSI Reports Strong Second Quarter 2025 Financial Results

- Revenues and Gross Billings up 10% to $307.7 Million and $2.23 Billion - - Announces New $100 Million Stock Repurchase Program -

What are the potential risks to maintaining this growth trajectory, such as cash flow constraints or market saturation? Are there any macro‑economic or industry headwinds that could offset the positive momentum shown in Q2? What is the expected impact of the repurchase program on existing shareholder dilution and future capital allocation?

Symbol: BBSI

Earnings

24 days ago

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes thr...

How will the recent business progress affect the company’s long‑term strategic objectives and share price trajectory? What macro‑economic or sector trends could intersect with Aligos’ reported performance? Did the release mention any non‑dilutive financing sources, such as grants or milestone payments?

Symbol: ALGS

Earnings

24 days ago